A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer (Q33387432)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Chul Kim

1

1 reference

Europe PubMed Central

26 July 2017

Jae-Lyun Lee

2

1 reference

Europe PubMed Central

26 July 2017

Min-Hee Ryu

3

1 reference

Europe PubMed Central

26 July 2017

Heung Moon Chang

4

1 reference

Europe PubMed Central

26 July 2017

Tae Won Kim

5

1 reference

Europe PubMed Central

26 July 2017

Ho Young Lim

6

1 reference

Europe PubMed Central

26 July 2017

Hye Jin Kang

7

1 reference

Europe PubMed Central

26 July 2017

Young Suk Park

8

1 reference

Europe PubMed Central

26 July 2017

Baek-Yeol Ryoo

9

1 reference

Europe PubMed Central

26 July 2017

Yoon-Koo Kang

10

1 reference

Europe PubMed Central

26 July 2017

publication date

9 December 2009

1 reference

Europe PubMed Central

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

26 July 2017

29

1 reference

Europe PubMed Central

26 July 2017

2

1 reference

Europe PubMed Central

26 July 2017

366-373

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-009-9363-0

0 references

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Novel targeted therapies in the treatment of gastric and esophageal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9363-0

21 January 2018

Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19997960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19997960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19997960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19997960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19997960

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-009-9363-0

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33387432&oldid=1991058101"